Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors.

Gholamin S, Mitra SS, Feroze AH, Liu J, Kahn SA, Zhang M, Esparza R, Richard C, Ramaswamy V, Remke M, Volkmer AK, Willingham S, Ponnuswami A, McCarty A, Lovelace P, Storm TA, Schubert S, Hutter G, Narayanan C, Chu P, Raabe EH, Harsh G 4th, Taylor MD, Monje M, Cho YJ, Majeti R, Volkmer JP, Fisher PG, Grant G, Steinberg GK, Vogel H, Edwards M, Weissman IL, Cheshier SH.

Sci Transl Med. 2017 Mar 15;9(381). pii: eaaf2968. doi: 10.1126/scitranslmed.aaf2968.

PMID:
28298418
2.

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.

Weiskopf K, Jahchan NS, Schnorr PJ, Cristea S, Ring AM, Maute RL, Volkmer AK, Volkmer JP, Liu J, Lim JS, Yang D, Seitz G, Nguyen T, Wu D, Jude K, Guerston H, Barkal A, Trapani F, George J, Poirier JT, Gardner EE, Miles LA, de Stanchina E, Lofgren SM, Vogel H, Winslow MM, Dive C, Thomas RK, Rudin CM, van de Rijn M, Majeti R, Garcia KC, Weissman IL, Sage J.

J Clin Invest. 2016 Jul 1;126(7):2610-20. doi: 10.1172/JCI81603. Epub 2016 Jun 13.

3.

CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer.

Cheah MT, Chen JY, Sahoo D, Contreras-Trujillo H, Volkmer AK, Scheeren FA, Volkmer JP, Weissman IL.

Proc Natl Acad Sci U S A. 2015 Apr 14;112(15):4725-30. doi: 10.1073/pnas.1424795112. Epub 2015 Mar 30.

4.

Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRPα variants.

Weiskopf K, Ring AM, Schnorr PJ, Volkmer JP, Volkmer AK, Weissman IL, Garcia KC.

Oncoimmunology. 2013 Sep 1;2(9):e25773. Epub 2013 Jul 29.

5.

Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors.

Edris B, Willingham S, Weiskopf K, Volkmer AK, Volkmer JP, Mühlenberg T, Weissman IL, van de Rijn M.

Oncoimmunology. 2013 Jun 1;2(6):e24452. Epub 2013 May 14.

6.

Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies.

Weiskopf K, Ring AM, Ho CC, Volkmer JP, Levin AM, Volkmer AK, Ozkan E, Fernhoff NB, van de Rijn M, Weissman IL, Garcia KC.

Science. 2013 Jul 5;341(6141):88-91. doi: 10.1126/science.1238856. Epub 2013 May 30.

7.

Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth.

Edris B, Willingham SB, Weiskopf K, Volkmer AK, Volkmer JP, Mühlenberg T, Montgomery KD, Contreras-Trujillo H, Czechowicz A, Fletcher JA, West RB, Weissman IL, van de Rijn M.

Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3501-6. doi: 10.1073/pnas.1222893110. Epub 2013 Feb 4.

8.

Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer.

Rein DT, Volkmer AK, Volkmer J, Beyer IM, Janni W, Fleisch MC, Welter AK, Bauerschlag D, Schöndorf T, Breidenbach M.

Oncol Lett. 2012 Mar;3(3):530-534. Epub 2012 Jan 3.

9.

Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma.

Edris B, Weiskopf K, Volkmer AK, Volkmer JP, Willingham SB, Contreras-Trujillo H, Liu J, Majeti R, West RB, Fletcher JA, Beck AH, Weissman IL, van de Rijn M.

Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6656-61. doi: 10.1073/pnas.1121629109. Epub 2012 Mar 26.

10.

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.

Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, Lovelace P, Scheeren FA, Chao MP, Weiskopf K, Tang C, Volkmer AK, Naik TJ, Storm TA, Mosley AR, Edris B, Schmid SM, Sun CK, Chua MS, Murillo O, Rajendran P, Cha AC, Chin RK, Kim D, Adorno M, Raveh T, Tseng D, Jaiswal S, Enger PØ, Steinberg GK, Li G, So SK, Majeti R, Harsh GR, van de Rijn M, Teng NN, Sunwoo JB, Alizadeh AA, Clarke MF, Weissman IL.

Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6662-7. doi: 10.1073/pnas.1121623109. Epub 2012 Mar 26.

Supplemental Content

Loading ...
Support Center